We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DAAs

News List

DAAs Cut Deaths in Those Treated for HCV-Related Liver Cancer drugs
August 21, 2019
Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for death...
Cure Hepatitis C in 8 Weeks: Maviret, the Hepatitis C Drug with the Best Efficacy in the World, has Entered China PharmaSources/1℃
June 04, 2019
The National Medical Products Administration of China (NMPA) has approved the marketing of AbbVie’s direct-acting antiviral (DAA) Maviret (glecaprevir/pibrentasvir) on May 15, 2019.
Global HCV Drug Market Declined to below USD10 Billion in 2018, with only AbbVie’s Mavyret Outshining PharmaSources/1℃
March 11, 2019
The global HCV drug market continued to shrink and reached USD7.767 billion in 2018.